Back to search results

Pilot Study for Panitumumab-IRDye800 in Brain Lesion Surgery

This study is testing a new imaging agent called panitumumab-IRDye800 (pan800) to see if it can help surgeons better see brain lesions during surgery. Pan800 is a fluorescent dye that targets a specific protein (EGFR) often found on these lesions. If you are an adult (18 years or older) scheduled for surgery to remove a brain lesion like meningioma, glioblastoma, acoustic neuroma, brain cancer, or pituitary adenoma, you might be able to join. The main goal is to check the safety of pan800. You would receive a single infusion of pan800 1-5 days before your scheduled surgery, and then doctors would use a special camera during your operation to see if the lesions light up. The study's current status is unclear, and it plans to enroll 30 participants.

Study design
This is a pilot study, meaning it's an early-stage investigation. It plans to enroll 30 participants.
What's involved
You would receive a single infusion of panitumumab-IRDye800 1-5 days before your surgery. You would then undergo your planned neurosurgical procedure with additional imaging, and be monitored for safety through postoperative assessments and a Day 15 follow-up contact.
Compensation
Not stated in the trial record.
Follow-up
You would be followed for safety from the infusion up to 15 days after the infusion.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07493447

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

Recruiting
EARLY_PHASE1Ages 18+InterventionalSupportive care
Eben Rosenthal
~30 participants
Updated 2026-06-30 on ClinicalTrials.gov
What's tested:Panitumumab-IRDye800

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Determine the safety of panitumumab-IRDye800 as an imaging agent in patients undergoing surgery for intracranial lesions.
Measured over From infusion to 15 days post-infusion.

Conditions

Meningioma
Glioblastoma
Acoustic Neuroma
Brain Cancer
Pituitary Adenoma

Explore related trials

GlioblastomaIntracranial LesionMeningiomaPituitary Neuroendocrine TumorVestibular SchwannomaSoluble Epidermal Growth Factor Receptor

NCT07493447

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Vanderbilt University Medical Center

    Nashville, Tennesseeno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Peter Morone, MD · PRINCIPAL_INVESTIGATOR · Vanderbilt University Medical Center

Who to contact

Makenna Brown
[email protected]
615-421-4370
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Subjects with intracranial lesions undergoing surgical removal as their standard of care will be eligible. These may include subjects status post chemotherapy and/or radiation or subjects who have undergone diagnostic biopsy for their original diagnosis and are deemed to be candidates for resection.
Subject age ≥ 18 years.
Adequate hematologic and end-organ function appropriate for surgery and panitumumab infusion as determined by routine preoperative evaluation or designee prior to infusion. If liver function, renal function, and hematologic laboratory test results are acceptable for elective surgery and panitumumab infusion, the patient is considered eligible for the study. Laboratory results will need to be obtained within 30 days prior to initiation of study treatment include:
Women of childbearing potential must have a negative pregnancy test within 7 days of study drug administration.
Ability to understand and willingness to sign a written informed document or written informed consent via a surrogate consent rider from the patients' healthcare decision maker.

Exclusion

Had a myocardial infarction, cerebrovascular accident, or uncontrolled chronic heart failure within 6 months prior to enrollment.
History of infusion reactions to any monoclonal antibody therapies.
Women who are currently pregnant or breastfeeding.
Participants presenting with a baseline QTcF interval \> than 480 milliseconds.
Magnesium or phosphorus lower than normal institutional values, and subject is symptomatic.
Patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.
Patients with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.
Patients with severe renal disease or anuria

What this trial measures

  • Determine the safety of panitumumab-IRDye800 as an imaging agent in patients undergoing surgery for intracranial lesions.From infusion to 15 days post-infusion.

    Safety will be defined by the number of Grade ≥ 2 AEs determined that are clinically significant and considered definitely or probably related to pan800. Safety data will be summarized by grade, severity, and type.